
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology [S. Y. Z., S. C. L., L. F. A-S., D. H., X. G., A. J. P. K-S.] and Division of Population Science [J. B.], Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111
E2F-1 is the best known ultimate transcription factor in the cyclin/cyclin-dependent kinase/retinoblastoma gene pathway and is probably involved in carcinogenesis and tumor progression. Because E2F-1 can be detected in paraffin sections using immunohistochemical techniques, it could be a useful tumor/proliferation marker. We studied the expression of this gene product in 130 breast tissue specimens from 100 patients and compared it with the expression of Mib-1, the widely used prognostic/proliferative marker, to assess E2F-1 as a new marker of neoplastic proliferation. The percentage of E2F-1-positive cells increased from 1.9% in the normal breast (NB) to 6.3% in ductal carcinoma in situ (DCIS) and to 15.3% in invasive ductal carcinomas (IDC). In addition, higher-grade tumors as well as advanced-stage disease correlated with higher expression of E2F-1. A similar tendency of Mib-1 expression was observed. There was a positive correlation between the E2F-1 and Mib-1 indices. In an in vitro experiment, we found that a similar difference in the expression of E2F-1 existed between a nontumorigenic breast cell line and two widely used breast carcinoma cell lines. The breast carcinoma cell lines T-47D and MCF-7 had more E2F-1-positive cells than the nontumorigenic cell line MCF-10F by immunohistochemistry and Western blot analysis. Because E2F-1 expression was significantly higher in IDC and DCIS than in NB, this study indicates that deregulation of E2F-1 may be involved in the development of breast IDC. In addition, E2F-1 expression could also be involved in tumor progression because the increased E2F-1 index correlated with the known prognostic predictors of breast cancer, such as histological grade, stage, metastasis status, estrogen receptor/progesterone receptor and Mib-1 expression. Thus, E2F-1 is a promising candidate to become a new prognostic/predictive marker of breast cancer.
This article has been cited by other articles:
![]() |
I. Molina-Privado, M. Rodriguez-Martinez, P. Rebollo, D. Martin-Perez, M.-J. Artiga, J. Menarguez, E. K. Flemington, M. A. Piris, and M. R. Campanero E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma Cancer Res., May 1, 2009; 69(9): 4052 - 4058. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-l. Huang, D. Liu, J. Nakano, H. Yokomise, M. Ueno, K. Kadota, and H. Wada E2F1 Overexpression Correlates with Thymidylate Synthase and Survivin Gene Expressions and Tumor Proliferation in Non Small-Cell Lung Cancer Clin. Cancer Res., December 1, 2007; 13(23): 6938 - 6946. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. X. Zou, A. S. Revenko, L. B. Li, A. T. Gemo, and H.-W. Chen ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ER{alpha}, is required for coregulator occupancy and chromatin modification PNAS, November 13, 2007; 104(46): 18067 - 18072. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Stender, J. Frasor, B. Komm, K. C. N. Chang, W. L. Kraus, and B. S. Katzenellenbogen Estrogen-Regulated Gene Networks in Human Breast Cancer Cells: Involvement of E2F1 in the Regulation of Cell Proliferation Mol. Endocrinol., September 1, 2007; 21(9): 2112 - 2123. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Verlinden, I. Vanden Bempt, G. Eelen, M. Drijkoningen, I. Verlinden, K. Marchal, C. De Wolf-Peeters, M.-R. Christiaens, L. Michiels, R. Bouillon, et al. The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast Carcinomas Cancer Res., July 15, 2007; 67(14): 6574 - 6581. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer, M. A. Rubin, and M. L. Day Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer Cancer Res., December 15, 2006; 66(24): 11897 - 11906. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-O. Yoon, S. Shin, and A. M. Mercurio Ras Stimulation of E2F Activity and a Consequent E2F Regulation of Integrin {alpha}6{beta}4 Promote the Invasion of Breast Carcinoma Cells. Cancer Res., June 15, 2006; 66(12): 6288 - 6295. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Louie, A. S. Revenko, J. X. Zou, J. Yao, and H.-W. Chen Direct Control of Cell Cycle Gene Expression by Proto-Oncogene Product ACTR, and Its Autoregulation Underlies Its Transforming Activity Mol. Cell. Biol., May 15, 2006; 26(10): 3810 - 3823. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, J. Tan, L. Zhuang, X. Jiang, E. T. Liu, and Q. Yu Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim PNAS, November 1, 2005; 102(44): 16090 - 16095. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Yamazaki, M Hasegawa, I Ohoka, K Hanami, A Asoh, T Nagao, I Sugano, and Y Ishida Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus J. Clin. Pathol., September 1, 2005; 58(9): 904 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Davis, M. T. McCabe, S. W. Hayward, J. M. Park, and M. L. Day Disruption of Rb/E2F Pathway Results in Increased Cyclooxygenase-2 Expression and Activity in Prostate Epithelial Cells Cancer Res., May 1, 2005; 65(9): 3633 - 3642. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Louie, J. X. Zou, A. Rabinovich, and H.-W. Chen ACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance Mol. Cell. Biol., June 15, 2004; 24(12): 5157 - 5171. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bourdeau, J. Deschenes, R. Metivier, Y. Nagai, D. Nguyen, N. Bretschneider, F. Gannon, J. H. White, and S. Mader Genome-Wide Identification of High-Affinity Estrogen Response Elements in Human and Mouse Mol. Endocrinol., June 1, 2004; 18(6): 1411 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kwong, T. V. Nguyen, R. J. Bova, J. G. Kench, I. E. Cole, E. A. Musgrove, S. M. Henshall, and R. L. Sutherland Overexpression of E2F-1 Is Associated with Increased Disease-free Survival in Squamous Cell Carcinoma of the Anterior Tongue Clin. Cancer Res., September 1, 2003; 9(10): 3705 - 3711. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ryo, Y.-C. Liou, K. P. Lu, and G. Wulf Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer J. Cell Sci., March 1, 2003; 116(5): 773 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ryo, Y.-C. Liou, G. Wulf, M. Nakamura, S. W. Lee, and K. P. Lu PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells Mol. Cell. Biol., August 1, 2002; 22(15): 5281 - 5295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Zhang, S. C. Liu, D. G. Johnson, and A. J. P. Klein-Szanto E2F-1 Gene Transfer Enhances Invasiveness of Human Head and Neck Carcinoma Cell Lines Cancer Res., November 1, 2000; 60(21): 5972 - 5976. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |